Picture of Molecular Templates logo

MTEM Molecular Templates Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-55.93%
3m-54.63%
6m-77.12%
1yr-71.85%
Volume Change (%)
10d/3m+187.69%
Price vs... (%)
52w High-80.42%
50d MA-46%
200d MA-67.98%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-108.03%
Return on Equity-478.86%
Operating Margin-46.05%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Molecular Templates EPS forecast chart

Profile Summary

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted biologic therapeutics. Its drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragment (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized Shiga-like toxin-A subunit (SLTA) and a class I antigen derived from the human cytomegalovirus (HCMV). pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 focuses on targeting CD38. CD38 is a single-chain type II transmembrane glycoprotein that is expressed by a variety of hematologic cells in an activation- and differentiation-dependent manner.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
October 17th, 2001
Public Since
February 4th, 2005
No. of Employees
222
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
5,374,268

MTEM Share Price Performance

Upcoming Events for MTEM

Q4 2023 Molecular Templates Inc Earnings Release

Q1 2024 Molecular Templates Inc Earnings Release

Q2 2024 Molecular Templates Inc Earnings Release

Similar to MTEM

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

FAQ